Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy G1 Therapeutics stock in Canada

Own G1 Therapeutics shares in just a few minutes.

G1 Therapeutics is a biotechnology business based in the US. G1 Therapeutics stocks (GTHX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $23.98 – an increase of 1% over the previous week. G1 Therapeutics employs 122 staff and has a trailing 12-month revenue of around $42.2 million.

How to buy shares in G1 Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GTHX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy G1 Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted G1 Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, G1 Therapeutics's stock price has had significant negative movement.

Its last market close was $10.11, which is 43.71% down on its pre-crash value of $17.96 and 14.89% up on the lowest point reached during the March crash when the stocks fell as low as $8.8.

If you had bought $1,000 worth of G1 Therapeutics stocks at the start of February 2020, those stocks would have been worth $527.95 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $500.24.

G1 Therapeutics stock price (NASDAQ:GTHX)

Use our graph to track the performance of GTHX stocks over time.

G1 Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$10.11
52-week range$9.31 - $37.07
50-day moving average $11.88
200-day moving average $16.67
Wall St. target price$41.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.28

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

G1 Therapeutics price performance over time

Historical closes compared with the close of $10.11 from 2022-01-14

1 week (2022-01-10) 4.33%
1 month (2021-12-17) -4.35%
3 months (2021-10-19) -24.33%
6 months (2021-07-19) -43.30%
1 year (2021-01-19) -53.39%
2 years (2020-01-17) -60.13%
3 years (2019-01-18) 20.13
5 years (2017-01-15) N/A

G1 Therapeutics financials

Revenue TTM $42.2 million
Gross profit TTM $45.3 million
Return on assets TTM -32.13%
Return on equity TTM -71.14%
Profit margin 0%
Book value $4.19
Market capitalisation $429.9 million

TTM: trailing 12 months

G1 Therapeutics share dividends

We're not expecting G1 Therapeutics to pay a dividend over the next 12 months.

G1 Therapeutics share price volatility

Over the last 12 months, G1 Therapeutics's shares have ranged in value from as little as $9.31 up to $37.069. A popular way to gauge a stock's volatility is its "beta".

GTHX.US volatility(beta: 2.08)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while G1 Therapeutics's is 2.0837. This would suggest that G1 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

G1 Therapeutics overview

G1 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc.

Stocks similar to G1 Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site